Orthocell Ltd has released a press release.
Orthocell: Replacement Trading Halt
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Orthocell
- Pause in Trading
- Remplir Approved to Commence Sales in US$84M Thai Market
- First US Distributors Signed for Remplirs US$1.6B market
- Regulatory Approval for Striate in US$65M Brazilian Market
- Remplir Cleared to Commence Sales in US$1.6B US Market
Later from Orthocell
- Remplir Approved to Commence Sales in US$75m Canadian Market
- 12 Distributors Signed for Remplir Covering 21 States in US
- Remplir Approved to Commence Sales in the Hong Kong Market
- Compelling Data Highlights Remplir Competitive Advantage
- First Surgical Use of Remplir in US$1.6 Billion US Market
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell